AA
SRPT icon

Ancora Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Ancora Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.9K Sell
2,500
-1,816
-42% -$34.3K ﹤0.01% 1090
2026
Q1 		$93.9K Buy
4,316
+1,497
+53% +$29K ﹤0.01% 923
2025
Q4 		$60.7K Buy
2,819
+1,319
+88% +$27.8K ﹤0.01% 1081
2025
Q3 		$28.9K Buy
1,500
+1,000
+200% +$17.8K ﹤0.01% 1150
2025
Q2 		$8.55K Hold
500
– – ﹤0.01% 1404
2025
Q1 		$31.9K Buy
500
+300
+150% +$31.6K ﹤0.01% 1103
2024
Q4 		$24.3K Buy
+200
New +$24.5K ﹤0.01% 1170

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Ancora Advisors's SRPT Position: Q2 2026 in Review

Ancora Advisors reduced its Sarepta Therapeutics (SRPT) stake by 42% in Q2 2026, selling an estimated $34.3K and leaving 2,500 shares worth $44.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1090.

Ancora Advisors first reported a position in SRPT in Q4 2024 and has held it in 7 quarters since. The position peaked at $93.9K in Q1 2026. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Ancora Advisors held 2,500 shares of Sarepta Therapeutics worth $44.9K as of Q2 2026.
  • Ancora Advisors sold 1,816 Sarepta Therapeutics shares in Q2 2026, an estimated $34.3K.
  • Sarepta Therapeutics made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #1090 holding.
  • Ancora Advisors first reported a position in Sarepta Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Ancora Advisors's Sarepta Therapeutics position peaked at $93.9K in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.